Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine for prevention of upper gastrointestinal lesions in patients on low-dose aspirin
2005-004849-33Phase 4Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of famotidine in Peptic ulcer disease (PUD), erosive esophagitis (EE) and Gastrointestinal injury, sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Development of gastric or duodenal ulcers or erosive oesophagitis. Started Nov 2005; status: completed.
02
Drugs
famotidine
03
Conditions
Peptic ulcer disease (PUD)erosive esophagitis (EE)Gastrointestinal injury
Beyond the preview
Go deeper on 2005-004849-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004849-33.